• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

治疗性疫苗诱导的HIV特异性淋巴细胞增殖性免疫反应的预测指标。

Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination.

作者信息

Moss R B, Wallace M R, Steigbigel R T, Morrison S A, Giermakowska W K, Nardo C J, Diveley J P, Carlo D J

机构信息

The Immune Response Corporation, Carlsbad, CA 92008, USA.

出版信息

Clin Exp Immunol. 2002 May;128(2):359-64. doi: 10.1046/j.1365-2249.2002.01835.x.

DOI:10.1046/j.1365-2249.2002.01835.x
PMID:11985528
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1906388/
Abstract

We treated a cohort of 38 HIV-infected individuals with a therapeutic vaccine (REMUNE, HIV-1 Immunogen) in an open label study. We then determined whether baseline parameters, such as CD4 cell count, viral load and IgG levels, were predictive of the magnitude of the HIV-specific lymphocyte proliferative responses (LPRs). We demonstrate herein that there is a significant enhancement from baseline for both HIV and p24 antigen-stimulated LPRs after immunization. Using a responder definition of a stimulation index of >5 on at least two post-immunization time-points, 29/38 (76%) responded to HIV-1 antigen while 27/38 (71%) responded to native p24 antigen. Viral load and total IgG were negatively correlated, while CD4 cell counts were positively associated with the magnitude of the HIV antigen LPR. In a multivariable analysis, baseline CD4 was the best predictor of HIV antigen LPR post-immunization.

摘要

在一项开放标签研究中,我们用一种治疗性疫苗(REMUNE,HIV-1免疫原)治疗了38名HIV感染个体的队列。然后我们确定基线参数,如CD4细胞计数、病毒载量和IgG水平,是否能预测HIV特异性淋巴细胞增殖反应(LPR)的程度。我们在此证明,免疫后HIV和p24抗原刺激的LPR与基线相比均有显著增强。使用在至少两个免疫后时间点刺激指数>5的应答者定义,29/38(76%)对HIV-1抗原产生应答,而27/38(71%)对天然p24抗原产生应答。病毒载量与总IgG呈负相关,而CD4细胞计数与HIV抗原LPR的程度呈正相关。在多变量分析中,基线CD4是免疫后HIV抗原LPR的最佳预测指标。

相似文献

1
Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination.治疗性疫苗诱导的HIV特异性淋巴细胞增殖性免疫反应的预测指标。
Clin Exp Immunol. 2002 May;128(2):359-64. doi: 10.1046/j.1365-2249.2002.01835.x.
2
Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects.
Viral Immunol. 1997;10(4):221-8. doi: 10.1089/vim.1997.10.221.
3
In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune).用灭活的去除gp120的HIV-1免疫原(Remune)免疫后,1型人类免疫缺陷病毒(HIV-1)血清阳性受试者体外p24抗原刺激的淋巴细胞增殖及β趋化因子产生情况
Clin Diagn Lab Immunol. 1998 May;5(3):308-12. doi: 10.1128/CDLI.5.3.308-312.1998.
4
Induction of specific T-cell responses in HIV infection.HIV感染中特异性T细胞应答的诱导
AIDS. 1998 Jan 22;12(2):157-66. doi: 10.1097/00002030-199802000-00005.
5
Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.候选治疗性疫苗p24病毒样颗粒联合齐多夫定在无症状受试者中的安全性和免疫原性。社区HIV研究网络调查人员。
AIDS. 1998 Jan 22;12(2):175-82. doi: 10.1097/00002030-199802000-00007.
6
The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs.
HIV Med. 2001 Apr;2(2):68-77. doi: 10.1046/j.1468-1293.2001.00051.x.
7
Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort.对一组HIV-1血清阳性人群中HIV-1特异性增殖反应、回忆抗原增殖反应及临床结局的前瞻性分析。
J Infect Dis. 2004 Jun 1;189(11):1988-95. doi: 10.1086/386285. Epub 2004 Apr 30.
8
Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.在慢性HIV-1感染患者中,一种联合白细胞介素-2的治疗性免疫接种的免疫学和病毒学疗效。
AIDS. 2005 Feb 18;19(3):279-86.
9
Cell-mediated immune responses to autologous virus in HIV-1-seropositive individuals after treatment with an HIV-1 immunogen.
AIDS. 2000 Nov 10;14(16):2475-8. doi: 10.1097/00002030-200011100-00008.
10
Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.晚期人类免疫缺陷病毒1型(HIV-1)感染者对重组人HIV-1糖蛋白160(gpl60)疫苗的免疫反应。马萨诸塞州gpl60工作组。
J Hum Virol. 2000 Jul-Aug;3(4):182-92.

引用本文的文献

1
Immune reconstitution and viral stimulation are required to restore HIV-specific CD8 T cell responses following advanced infection.晚期感染后,需要免疫重建和病毒刺激来恢复HIV特异性CD8 T细胞反应。
J Clin Immunol. 2004 Mar;24(2):115-24. doi: 10.1023/B:JOCI.0000019776.38147.e6.
2
Antigen-presenting cell modulation induces a memory response to p24 in peripheral blood leukocytes from human immunodeficiency virus-infected individuals.抗原呈递细胞调节可诱导人类免疫缺陷病毒感染个体外周血白细胞对p24产生记忆反应。
Clin Diagn Lab Immunol. 2003 Sep;10(5):757-63. doi: 10.1128/cdli.10.5.757-763.2003.

本文引用的文献

1
Investigations of the use of beta-propiolactone in virus inactivation.β-丙内酯在病毒灭活中的应用研究。
Ann N Y Acad Sci. 1960 Jan 13;83:578-94. doi: 10.1111/j.1749-6632.1960.tb40931.x.
2
The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs.
HIV Med. 2001 Apr;2(2):68-77. doi: 10.1046/j.1468-1293.2001.00051.x.
3
Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial.对 CD4 细胞计数为 300 至 549×10⁶/L 的 HIV 感染患者给予 HIV-1 免疫原(一种免疫调节剂)的评估:一项随机对照试验。
JAMA. 2000 Nov 1;284(17):2193-202. doi: 10.1001/jama.284.17.2193.
4
Immune control of HIV-1 after early treatment of acute infection.急性感染早期治疗后HIV-1的免疫控制
Nature. 2000 Sep 28;407(6803):523-6. doi: 10.1038/35035103.
5
Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.
J Infect Dis. 2000 Nov;182(5):1357-64. doi: 10.1086/315860. Epub 2000 Oct 9.
6
T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART).人类免疫缺陷病毒(HIV)-1感染中T细胞分裂主要归因于免疫激活:对接受高效抗逆转录病毒治疗(HAART)之前及治疗期间患者的纵向分析
Blood. 2000 Jan 1;95(1):249-55.
7
Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group.重组糖蛋白160作为治疗性艾滋病疫苗:一项大型随机对照试验的结果。欧洲多国免疫艾滋病疫苗研究小组
AIDS. 1999 Aug 20;13(12):1461-8. doi: 10.1097/00002030-199908200-00004.
8
Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response.三种b型流感嗜血杆菌蛋白结合疫苗在HIV血清阳性成人中的免疫原性及疫苗反应预测因素分析
Vaccine. 1999 Jul 16;17(22):2779-85. doi: 10.1016/s0264-410x(99)00089-4.
9
Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study.早期HIV感染期间的高效抗逆转录病毒疗法可逆转T细胞活化和成熟异常。瑞士HIV队列研究。
AIDS. 1998 Nov 12;12(16):2115-23. doi: 10.1097/00002030-199816000-00006.
10
Anti-F(ab')2 antibody in HIV type 1 infection: relationship to hypergammaglobulinemia and to antibody specific to the V3 loop region of glycoprotein 120.1型人类免疫缺陷病毒感染中的抗F(ab')2抗体:与高丙种球蛋白血症及糖蛋白120 V3环区特异性抗体的关系
AIDS Res Hum Retroviruses. 1998 Apr 10;14(6):491-8. doi: 10.1089/aid.1998.14.491.